Executive SummaryPlans to begin clinicals immediately on a combination of Proleukin (interleukin-2) and tumor necrosis factor (TNF), two therapeutic anticancer agents. Accoring to Cetus, Proleukin and TNF, when used together, may have a synergistic effect in killing a variety of tumors. Preclinical animal studies show the combination to be more effective than either agent alone, firm says.
You may also be interested in...
Sleep apnea treatment company ResMed Corp. will pay $39.5m to settle allegations that it violated the False Claims Act by giving free or discounted goods and services to distributors and health-care providers to encourage the use of the firm’s devices.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.